Search results
Showing 101 to 150 of 1517 results for patients and public
In development Reference number: GID-TA11633 Expected publication date: 18 June 2026
Finerenone for treating heart failure with preserved or mildly reduced ejection fraction [ID6514]
In development Reference number: GID-TA11651 Expected publication date: 04 June 2026
Seladelpar for previously treated primary biliary cholangitis [ID6429]
In development Reference number: GID-TA11540 Expected publication date: TBC
Inhaled treprostinil for treating pulmonary hypertension with interstitial lung disease [ID6459]
In development Reference number: GID-TA11572 Expected publication date: 21 May 2026
Read biographies for all members of NICE's indicator advisory committee.
expenditure. You'll find this in the finance and workforce report section in our public board papers. Annual report (PDF) . This...
Pembrolizumab with chemoradiation for untreated high-risk locally advanced cervical cancer [ID6138]
Awaiting development Reference number: GID-TA11215 Expected publication date: 07 May 2026
Read biographies for all members of NICE's indicator advisory committee.
In development Reference number: GID-TA10143 Expected publication date: TBC
In development Reference number: GID-TA10990 Expected publication date: TBC
Involving you in the development of NICE guidance.
Involving you in the development of NICE guidance.
Lenacapavir for preventing HIV-1 in people aged 16 years or older [ID6495]
In development Reference number: GID-TA11638 Expected publication date: TBC
This quality standard covers ways to reduce suicide and help people bereaved or affected by suicide. It describes high-quality care in priority areas for improvement.
View quality statements for QS189Show all sections
Sections for QS189
- Quality statements
- Quality statement 1: Multi-agency suicide prevention partnerships
- Quality statement 2: Reducing access to methods of suicide
- Quality statement 3: Media reporting
- Quality statement 4: Involving family, carers or friends
- Quality statement 5: Supporting people bereaved or affected by a suspected suicide
- Update information
- About this quality standard
In development Reference number: GID-TA11488 Expected publication date: 15 July 2026
In development Reference number: GID-TA11498 Expected publication date: 29 April 2026
This guideline covers rehabilitation strategies for adults who have experienced a critical illness and stayed in critical care. It aims to improve physical, psychological and cognitive outcomes in people who have been discharged from critical care.
An outline of the roles and responsibilities of the National Institute for Health and Care Excellence.
In development Reference number: GID-TA11330 Expected publication date: TBC
How voluntary and community sector organisations can help us develop guidance
How voluntary and community sector (VCS) organisations can help NICE develop guidance
How voluntary and community sector organisations can help us develop guidance
How voluntary and community sector (VCS) organisations can help NICE develop guidance
Port Delivery Platform with ranibizumab for treating wet age-related macular degeneration [ID3983]
Awaiting development Reference number: GID-TA10879 Expected publication date: 11 November 2026
This quality standard covers testing, diagnosing and managing hepatitis B in adults, young people and children (from birth). It describes high-quality care in priority areas for improvement.
View quality statements for QS65Show all sections
Sections for QS65
- Quality statements
- Quality statement 1: Testing and vaccination for hepatitis B
- Quality statement 2: Referral for specialist care
- Quality statement 3: Referral to and assessment by specialist care for pregnant women who are identified as hepatitis B surface antigen-positive at antenatal screening
- Quality statement 4: Complete course of neonatal hepatitis B vaccination and blood testing at 12 months
- Quality statement 5: Personalised care plan
- Quality statement 6: Monitoring people with chronic hepatitis B infection who do not meet the criteria for antiviral treatment
- Quality statement 7: 6-monthly surveillance testing for hepatocellular carcinoma in adults with chronic hepatitis B infection who have significant liver fibrosis or cirrhosis
In development Reference number: GID-TA11186 Expected publication date: TBC
In development Reference number: GID-TA11298 Expected publication date: TBC
This document is one of a series describing the processes and methods that NICE uses to carry out technology appraisals. It focuses on the technology appraisal processes
This guideline covers managing hip fracture in adults. It aims to improve care from the time people aged 18 and over are admitted to hospital through to when they return to the community. Recommendations emphasise the importance of early surgery and coordinating care through a multidisciplinary Hip Fracture Programme to help people recover faster and regain their mobility.
This guideline covers how to make shared decision making part of everyday care in all healthcare settings. It promotes ways for healthcare professionals and people using services to work together to make decisions about treatment and care. It includes recommendations on training, communicating risks, benefits and consequences, using decision aids, and how to embed shared decision making in organisational culture and practices.
This guideline covers how to identify adults at high risk of type 2 diabetes. It aims to remind practitioners that age is no barrier to being at high risk of, or developing, the condition. It also aims to help them provide those at high risk with an effective and appropriate intensive lifestyle-change programme to prevent or delay the onset of type 2 diabetes. The recommendations in this guideline can be used alongside the NHS Health Check programme .
Palopegteriparatide for treating chronic hypoparathyroidism [ID6380]
In development Reference number: GID-TA11454 Expected publication date: 23 July 2026
In development Reference number: GID-TA11649 Expected publication date: 14 October 2026
Find out more about the types of organisations that can register to be a stakeholder at NICE.
Find out more about the types of organisations that can register to be a stakeholder at NICE.
In development Reference number: GID-TA11230 Expected publication date: 07 May 2026
This quality standard covers the mental wellbeing of older people (aged 65 and over) receiving care in care homes (including residential and nursing accommodation, day care and respite care). It focuses on support for people to improve their mental wellbeing so that they can stay as well and independent as possible. It describes high-quality care in priority areas for improvement.
View quality statements for QS50Show all sections
Sections for QS50
- Quality statements
- Quality statement 1: Participation in meaningful activity
- Quality statement 2: Personal identity
- Quality statement 3: Recognition of mental health conditions
- Quality statement 4: Recognition of sensory impairment
- Quality statement 5: Recognition of physical problems
- Quality statement 6: Access to healthcare services
- Update information
a rapid assessment of flu product zanamivir. First public board meeting Register to attend a public board meeting . 2000...
HIV testing: increasing uptake among people who may have undiagnosed HIV (NG60)
This guideline covers how to increase the uptake of HIV testing in primary and secondary care, specialist sexual health services and the community. It describes how to plan and deliver services that are tailored to the local prevalence of HIV, promote awareness of HIV testing and increase opportunities to offer testing to people who may have undiagnosed HIV.
In development Reference number: GID-TA11140 Expected publication date: TBC
In development Reference number: GID-TA11232 Expected publication date: 08 April 2026
People and communities - putting you at the heart of our work
NICE is committed to involving people who use services, carers and the public in the development of our guidance and other products.
People and communities - putting you at the heart of our work
NICE is committed to involving people who use services, carers and the public in the development of our guidance and other products.
Clostridioides difficile infection: antimicrobial prescribing (NG199)
This guideline sets out an antimicrobial prescribing strategy for managing Clostridioides difficile infection in adults, young people and children aged 72 hours and over in community and hospital settings. It aims to optimise antibiotic use and reduce antibiotic resistance. The recommendations do not cover diagnosis.
CaRi-Heart for predicting cardiac risk in adults with suspected coronary artery disease (CAD)
In development Reference number: GID-HTE10085 Expected publication date: TBC
In development Reference number: GID-TA10979 Expected publication date: 11 March 2026
Find out more about NICE technology appraisals advisory committee D members
Read the biographies of our medical technologies advisory committee members.
This guideline covers safe and effective use of medicines in health and social care for people taking 1 or more medicines. It aims to ensure that medicines provide the greatest possible benefit to people by encouraging medicines reconciliation, medication review, and the use of patient decision aids.
Rozanolixizumab for treating antibody-positive generalised myasthenia gravis [ID5092]
In development Reference number: GID-TA10994 Expected publication date: TBC
This guideline aims to increase the uptake of all vaccines provided on the NHS routine UK immunisation schedule by everyone who is eligible. It supports the aims of the NHS Long Term Plan , which includes actions to improve immunisation coverage by GPs (including the changes to vaccinations and immunisations detailed in the 2021/2022 and 2022/23 GP contracts ) and support a narrowing of health inequalities.
Tezepelumab for treating severe chronic rhinosinusitis with nasal polyps ID6379
In development Reference number: GID-TA11429 Expected publication date: 09 September 2026